- Home
- VTAK vs VBIO Comparison
VTAK vs VBIO Comparison
Compare VTAK & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTAK | VBIO |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | 52 |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VTAK | VBIO |
|---|---|---|
| Price | $0.28 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 853.4K |
| Earning Date | 08-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $442,000.00 | N/A |
| Revenue This Year | $1,170.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3057.14 | N/A |
| 52 Week Low | $0.23 | $0.25 |
| 52 Week High | $4.31 | $0.61 |
Technical Indicators
Market Signals| Indicator | VTAK | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 32.74 |
| Support Level | $0.23 | $0.25 |
| Resistance Level | $0.93 | $0.43 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 13.57 | 10.44 |
Price Performance
Historical ComparisonAbout VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.